Physician profile
Robert Buckingham
NPI 1023147675
$706.55
in general payments reported to CMS, 2019-2025
14 companies · $47.50 in 2025
The $47.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.66 · 2020: $77.96 · 2021: $185 · 2022: $117 · 2023: $168 · 2024: $76.33 · 2025: $47.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $181.03 | 2020-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $146.86 | 2019-2021 | |
| Novo Nordisk INC | $63.57 | 2021-2023 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $49.30 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.12 | 2023-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $44.92 | 2023 | |
| Neurocrine Biosciences, INC. | $37.80 | 2023 | Ingrezza |
| Pfizer INC. | $33.48 | 2023 | |
| Eisai INC. | $20.32 | 2021 | |
| Lilly USA, LLC | $20.31 | 2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.26 | 2022 | |
| Bioventus LLC | $16.10 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.82 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.66 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Buckingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.